Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient

Table 1 The titers of anti-C.E.R.A. and anti-epoetin-beta antibodies

	Anti-C.E.R.A. antibody				Anti-epoetin-beta antibody
	1^st assay		2^st assay		1^st assay		2^st assay
	Titer	Normal range	Value (%)	Normal range	Titer	Normal range	Value (%)	Normal range
At diagnosis	0.0275	≦ 0.0123	79.6	≦ 55.6	1.1202	≦ 0.3973	94.4	≦ 15.6
On the 20th week after the therapy	0.0075	≦ 0.0125			0.125	≦ 0.1858
On the 32th week after the therapy	0.015	≦ 0.0235			0.1045	≦ 0.196
On the 20th week after the re-administration	0.0165	≦ 0.0283			0.104	≦ 0.1633

1^st assay represents the titer of anti-C.E.R.A. or anti-epoetin-beta antibody determined using an enzyme-linked immunosorbent assay
2^st assay shows the decline rate in the titer of anti-C.E.R.A. or anti-epoetin-beta antibody when excess recombinant C.E.R.A. or epoetin-beta proteins was added

ISSN: 1471-2369